Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 987
- Registration Number
- NCT00856986
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Welwyn Garden City, United Kingdom
Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia AHaemophilia B
- Interventions
- Drug: activated recombinant human factor VII
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 139
- Registration Number
- NCT00853086
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom
Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects
- First Posted Date
- 2009-02-26
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 84
- Registration Number
- NCT00851773
Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney Disease
Withdrawn
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Chronic Kidney Disease
- Interventions
- First Posted Date
- 2009-02-23
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT00849316
Observational Study on Levemir® in Obese Diabetic Patients
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-02-23
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 580
- Registration Number
- NCT00849342
Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3421
- Registration Number
- NCT00842894
Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 66
- Registration Number
- NCT00842361
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tagajo-shi, Japan
An Observational Study in Type 2 Diabetic Patients on Oral Antidiabetic Drugs and Basal Insulin in Near East Countries
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2155
- Registration Number
- NCT00842192
- Locations
- 🇵🇰
Novo Nordisk Investigational Site, Karachi, Pakistan
Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes
Phase 2
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 65
- Registration Number
- NCT00841087
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Japan
Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects
Phase 3
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2017-03-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 150
- Registration Number
- NCT00840086
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath